Immune thrombotic thrombocytopenic purpura: Personalized therapy using ADAMTS‐13 activity and autoantibodies

Recently, treatment of immune‐mediated thrombotic thrombocytopenic purpura (ITTP) has changed with the advent of caplacizumab in clinical practice. The International Working Group (IWG) has recently integrated the ADAMTS‐13 activity/autoantibody monitoring in consensus outcome definitions. We report...

Descripción completa

Detalles Bibliográficos
Autores principales: Palandri, Francesca, Di Pietro, Christian, Ricci, Francesca, Tazzari, Pier Luigi, Randi, Vanda, Bartoletti, Daniela, Cavo, Michele, Vianelli, Nicola, Auteri, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8660682/
https://www.ncbi.nlm.nih.gov/pubmed/34938937
http://dx.doi.org/10.1002/rth2.12606

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8660682/
https://www.ncbi.nlm.nih.gov/pubmed/34938937
http://dx.doi.org/10.1002/rth2.12606

Ejemplares similares